[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Sengar AR, Kulkarni JN: Growing teratoma syndrome in a post laparoscopic excision of ovarian immature teratoma. J Gynecol Oncol; 2010 Jun;21(2):129-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growing teratoma syndrome in a post laparoscopic excision of ovarian immature teratoma.
  • A 26-year-old girl was referred to us in December 2008 with progressive pelvic mass while on chemotherapy.
  • In September 2008, she developed recurrent pelvic mass with AFP levels of 2,400 ng/mL.
  • Three courses of chemotherapy (bleomycin-etoposide-cisplatin) were given.
  • Post-chemotherapy AFP normalized but tumor size increased.
  • With provisional diagnosis of growing teratoma syndrome she had exploratory laparotomy with excision of pelvic mass along with sigmoid colon, excision of right pelvic and subcutaneous deposits, omentectomy and sigmoid anastomosis.
  • Left ovary, left tube and uterus appeared normal and were preserved.
  • Growing teratoma syndrome is a clinico-pathological presentation during/post-chemotherapy in malignant ovarian germ cell tumor where mature teratoma grows and requires complete surgical excision.
  • Our case highlights the safety and adequacy concerns of laparoscopic management of malignant ovarian tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1992 Jul;46(1):111-4 [1634130.001]
  • [Cites] Clin Radiol. 1991 Jun;43(6):402-8 [2070582.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1629-35 [6288220.001]
  • [Cites] Obstet Gynecol. 1977 Mar;49(3):346-50 [65751.001]
  • [Cites] Gynecol Oncol. 1993 Jun;49(3):395-9 [8314544.001]
  • [Cites] Eur J Cancer. 2000 Jul;36(11):1389-94 [10899652.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):83-7 [18307026.001]
  • [Cites] Gynecol Oncol. 1994 Mar;52(3):287-91 [8157184.001]
  • (PMID = 20613905.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2895713
  • [Keywords] NOTNLM ; Chemotherapy / Growing teratoma syndrome / Immature teratoma / Laparoscopy / Malignant ovarian germ cell tumor / Salpingo-oophorectomy
  •  go-up   go-down


2. Swenson MM, MacLeod JS, Williams SD, Miller AM, Champion VL: Quality of life after among ovarian germ cell cancer survivors: a narrative analysis. Oncol Nurs Forum; 2003 May-Jun;30(3):380
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life after among ovarian germ cell cancer survivors: a narrative analysis.
  • PURPOSE/OBJECTIVES: To describe and interpret the meaning of experiences that are important to the quality of living of ovarian germ cell cancer survivors.
  • Anderson Cancer Center in Houston.
  • PARTICIPANTS: 109 women between the ages of 19-64 (median age = 36) who were enrolled on prospective clinical trials of cisplatin-based chemotherapy after surgery and disease-free for at least two years.
  • INTERPRETATION: In addition to measuring physical, psychological, and sexual functioning in women surviving ovarian germ cell cancer, nurses also must understand how these issues fit into their everyday lived experiences.
  • The four themes may help clinicians and researchers to understand issues that are important to the quality of living of ovarian germ cell cancer survivors.
  • [MeSH-major] Health Knowledge, Attitudes, Practice. Neoplasms, Germ Cell and Embryonal / psychology. Ovarian Neoplasms / psychology. Quality of Life. Survivors / psychology. Survivors / statistics & numerical data

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12719752.001).
  • [ISSN] 1538-0688
  • [Journal-full-title] Oncology nursing forum
  • [ISO-abbreviation] Oncol Nurs Forum
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA77470
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


3. Kusamura S, Teixeira LC, dos Santos MA, de Angelo Andrade LA, Campos Torres JC, Sagarra A, Deraco M, Derchain SF: Ovarian germ cell cancer: clinicopathologic analysis and outcome of 31 cases. Tumori; 2000 Nov-Dec;86(6):450-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian germ cell cancer: clinicopathologic analysis and outcome of 31 cases.
  • AIMS: The aim of the study was to evaluate some clinicopathologic characteristics and the outcome of patients with ovarian germ cell cancer (OGCC) treated with cisplatin-based chemotherapy.
  • Women with dysgerminoma and nondysgerminomatous tumors did not present differences regarding surgical staging, age, ascites or residual tumor after the initial surgery.
  • Frozen section, performed in 16 patients, showed some discrepancy with paraffin histology diagnosis in 8 patients.
  • Platinum-based chemotherapy was used in 5/10 patients with dysgerminoma and in 17/21 patients with nondysgerminomatous tumors, with a 5-year survival of 100% for the dysgerminoma and 53% for the nondysgerminomatous group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dysgerminoma / diagnosis. Dysgerminoma / therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Biopsy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Follow-Up Studies. Frozen Sections. Humans. Neoplasm, Residual. Prognosis. Reoperation. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11218184.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M, Rosti G, Champion KM, Secondino S, Selle F, Ketterer N, Grignani G, Siena S, Demirer T, European Group for Blood and Marrow Transplantation (EBMT) Solid Tumors Working Party: High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol; 2006 Oct;17(10):1479-88
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults.
  • Since the early 1980s high dose chemotherapy with autologous hematopoietic stem cell support was adopted by many oncologists as a potentially curative option for solid tumors, supported by a strong rationale from laboratory studies and apparently convincing results of early phase II studies.
  • As a result, the number and size of randomized trials comparing this approach with conventional chemotherapy initiated (and often abandoned before completion) to prove or disprove its value was largely insufficient.
  • In fact, with the possible exception of breast carcinoma, the benefit of a greater escalation of dose of chemotherapy with stem cell support in solid tumors is still unsettled and many oncologists believe that this approach should cease.
  • In this article, we critically review and comment on the data from studies of high dose chemotherapy so far reported in adult patients with small cell lung cancer, ovarian cancer, germ cell tumors and sarcomas.

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16547069.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 96
  •  go-up   go-down


5. Sueblinvong T, Noophun P, Pataradool K, Suwanwela N, Phanthumchinda K, Tresukosol D: Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary. J Obstet Gynaecol Res; 2002 Apr;28(2):99-103
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.
  • A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.
  • The clinicoradiologic features in this patient were consistent with posterior leukoencephalopathy, which is a rare complication of chemotherapy.
  • This syndrome has been previously reported following cisplatin-based chemotherapy.
  • Physicians should remain alert to the potential hazards of chemotherapy to the central nervous system.
  • Risks and benefits should be seriously considered before starting treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brain Diseases / chemically induced. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Bleomycin / adverse effects. Cisplatin / adverse effects. Electroencephalography. Female. Humans. Magnetic Resonance Imaging. Phenytoin / therapeutic use. Seizures / drug therapy. Seizures / etiology. Tomography, X-Ray Computed. Vinblastine / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. PHENYTOIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12078977.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anticonvulsants; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 6158TKW0C5 / Phenytoin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, Williams SD, Gynecologic Oncology Group: Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol; 2007 Jul 1;25(19):2792-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study.
  • PURPOSE: To compare malignant ovarian germ cell tumor survivors with a matched control group of females on menstrual and reproductive outcomes, sexual functioning, and dyadic adjustment.
  • (1) history of malignant ovarian germ cell tumor;.
  • (2) treatment with surgery plus platinum-based chemotherapy;.
  • Twenty-four survivors reported 37 offspring after cancer treatment.
  • CONCLUSION: Women who had fertility-sparing surgery were very likely to retain menstrual function and fertility after chemotherapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cisplatin / adverse effects. Cisplatin / therapeutic use. Infertility, Female / etiology. Neoplasms, Germ Cell and Embryonal / complications. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / complications. Ovarian Neoplasms / drug therapy. Sexual Dysfunction, Physiological / etiology
  • [MeSH-minor] Adult. Case-Control Studies. Female. Fertility. Humans. Middle Aged. Reproductive Behavior. Time Factors


7. Kang H, Kim TJ, Kim WY, Choi CH, Lee JW, Kim BG, Bae DS: Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol; 2008 Oct;111(1):106-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
  • OBJECTIVE: The aim of this study was to investigate the outcome and reproductive function of patients with ovarian endodermal sinus tumor (EST) after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP).
  • METHODS: Between 1995 and 2006, 1034 patients with the diagnosis of ovarian cancer were treated at a single institution.
  • Among these patients, 51 had a confirmed diagnosis of malignant ovarian germ cell tumor (MOGCT) including 20 cases of EST.
  • We retrospectively reviewed those patients with EST, who received BEP as adjuvant chemotherapy.
  • Of the 15 patients who were treated with fertility-sparing surgery, all had regular menstruation following the completion of adjuvant chemotherapy, and two of these patients had pregnancies with live birth deliveries and no complications.
  • CONCLUSION: In patients with EST, the cumulative high-dose BEP regimen resulted in excellent overall survival and did not seem to impair ovarian function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / physiopathology. Fertility. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / physiopathology. Ovary / physiopathology
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Bleomycin / adverse effects. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gynecologic Surgical Procedures / methods. Humans. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656249.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


8. Raveendran A, Gupta S, Bagga R, Saha SC, Gainder S, Dhaliwal LK, Patel F, Dey P, Nijhawan R: Advanced germ cell malignancies of the ovary: should neo-adjuvant chemotherapy be the first line of treatment? J Obstet Gynaecol; 2010 Jan;30(1):53-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced germ cell malignancies of the ovary: should neo-adjuvant chemotherapy be the first line of treatment?
  • Malignant germ cell tumours of the ovary, though classically known for 'young age' and 'early stage' at presentation, are not uncommonly identified at advanced stages.
  • Little is available in literature on the role of neo-adjuvant chemotherapy (NACT) in this group of tumours.
  • Two patients with advanced stage ovarian germ cell tumours, including one with 45XO/46XY chromosomal mosaicism, were treated at our Institute with neo-adjuvant chemotherapy with Bleomycin, Etoposide and Cisplatin followed by surgery.
  • Besides marked clinical improvement, intraoperatively both the patients presented no difficulty otherwise expected with widespread tumours, and histopathology report revealed no evidence of viable tumour.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20121506.001).
  • [ISSN] 1364-6893
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Sugiyama T, Ohta S, Tomonari R, Kamura T: [Treatment of malignant ovarian germ cell tumor and sex cord tumors]. Gan To Kagaku Ryoho; 2002 Aug;29(8):1358-62
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of malignant ovarian germ cell tumor and sex cord tumors].
  • We outline chemotherapy mainly for malignant ovarian germ cell and sex-cord tumors, based on studies in the literature and our own clinical experiences.
  • With both tumors, PEB treatment is standard adjuvant chemotherapy.
  • With regard to the number of dosage courses, 4 courses are regarded as tolerable after incomplete reduction, and 3 courses as adjuvant treatment after complete extraction.
  • This chemotherapy is effective for preservation of fertility in young patients with malignant ovarian germ cell tumor.
  • In both tumors, some cases show chemotherapy resistance.
  • An effective second-line treatment strategy using a new anticancer agent needs to be established for such cases in the future.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Ovarian Neoplasms / drug therapy. Sex Cord-Gonadal Stromal Tumors / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Child. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • Genetic Alliance. consumer health - Ovarian germ cell tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214461.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; BEP protocol; PVB protocol; VAC protocol
  • [Number-of-references] 19
  •  go-up   go-down


10. Lobaplatin: D 19466. Drugs R D; 2003;4(6):369-72
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lobaplatin [D 19466] is a platinum complex with DNA alkylating activity that was developed by ASTA Medica (Degussa) for the treatment of cancer.
  • ASTA Medica discontinued development of lobaplatin, and subsequent development of the compound became the responsibility of Zentaris AG (AEterna Laboratories), which was formed in 2001 from the biopharmaceutical, inhalation technology and gene therapy activities of ASTA Medica.
  • Cisplatin, one of the original platinum compounds, has had a major impact on the treatment of solid tumours such as germ cell cancer, ovarian cancer, bladder cancer and bronchial carcinoma, but its clinical usefulness is limited by renal, neurological and gastrointestinal toxicity.
  • This has led to the development of second- and third-generation platinum analogues, such as lobaplatin, with reduced toxicity and a better therapeutic index.
  • The technology transfer agreement provides for Zentaris to receive a one-time payment to the amount of 4.5 million Canadian dollars.
  • Lobaplatin has been approved in China for the treatment of chronic myelogenous leukaemia (CML) and inoperable, metastatic breast and small cell lung cancer.
  • Lobaplatin has also completed phase II clinical trials in the US, Australia, EU, Brazil and South Africa for the treatment of various cancers, including breast, oesophageal, lung and ovarian cancers as well as CML.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Cyclobutanes / therapeutic use. Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14584968.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Cyclobutanes; 0 / Organoplatinum Compounds; OX5XK1JD8C / lobaplatin
  • [Number-of-references] 11
  •  go-up   go-down


11. Popadiuk S, Korzon M, Chybicka A, Szmyd K, Dzierzega M, Trelińska J, Kowalczyk JR, Wiśniewska-Slusarz H, Woźniak W, Bilska K, Wachowiak J, Konatkowska B, Wysocki M, Krawczuk-Rybak M, Czauderna P, Szumera M, Sznurkowska K, Renke J: [Ovarian malignant tumours. Efficacy of germ cell and sex cord tumour treatment protocol in Poland]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):803-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian malignant tumours. Efficacy of germ cell and sex cord tumour treatment protocol in Poland].
  • Approximately 1% of all malignant tumours among children are localized in the ovary.
  • The majority belongs to germ cell tumours and occurs in the peripubertal period.
  • AIM of the study was the evaluation of the efficacy of malignant ovarian germ cell tumour treatment programme in children.
  • MATERIAL AND METHODS: Since 1998, 40 girls with malignant ovarian tumours were enrolled in the multicentre trial.
  • Mixed germ cell tumours with yolk sac elements and dysgerminoma occurred the most often.
  • Tumour exceeded the ovary margin in more than half the patients and 25% were qualified as high risk group.
  • 38 children completed the treatment.
  • All but one patient with neuroblastoma received TGM protocol (Tumeurs Germinates Malignes).
  • A VBP regimen (vinblastine, bleomycin, cisplatin) was applied in 19 girls, VIP regimen (etoposide, ifosfamide, cisplatin) in 16, two received no chemotherapy.
  • Due to delayed remission after first-line chemotherapy it was prolonged with ABK (adriamycine, bleomycine, carboplatin) in 3 patients, 1 megachemotherapy regimen with autologous bone marrow transplantation was realized, one patient received a 1.5 year long oral chemotherapy.
  • RESULTS: Among 34 children with germ cell tumours and 3 with sex cord tumours who completed the treatment all are alive in the first remission.
  • 1 child with neuroblastoma localised in the ovary died due to recurrence.
  • CONCLUSIONS: The TGM protocol appears to be highly efficient in treatment of germ cell tumours even in advanced stages.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy. Sex Cord-Gonadal Stromal Tumors / drug therapy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Bone Marrow Transplantation. Carboplatin / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Poland. Remission Induction. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317911.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Poland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; COB protocol; ICE protocol 1
  •  go-up   go-down


12. Dacha S, Reddivari AK, Latta S, Devidi M, Iroegbu N: Carboplatin Induced Fatal Autoimmune Hemolytic Anemia: First Reported Case. World J Oncol; 2010 Aug;1(4):173-175

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carboplatin is an alkylating anti-neoplastic drug used in various cancers especially ovarian cancer, germ cell tumors, endometrial cancer besides others.
  • We present a case of acute autoimmune hemolytic anemia during Carboplatin infusion in a patient previously exposed to the drug, resulting in the death of the patient.
  • Published reports of Carboplatin induced autoimmune hemolytic anemia suggest these are usually nonfatal and improve after discontinuation of the drug.
  • A 77-year-old Caucasian lady with history of endometrial adenocarcinoma was receiving treatment with a combination of Carboplatin and Paclitaxel for recurrent adenocarcinoma presenting as a pelvic mass.
  • She tolerated similar chemotherapy previously, except for mild side effects.
  • During her fifth cycle of chemotherapy with Carboplatin, she suddenly collapsed in the infusion center.
  • Despite aggressive treatment, she expired within seven hours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):85-6 [3342471.001]
  • [Cites] Transfusion. 1988 Sep-Oct;28(5):493-5 [3420679.001]
  • [Cites] Anticancer Drugs. 1995 Apr;6(2):324-6 [7795280.001]
  • [Cites] Clin Lab Sci. 1999 Mar-Apr;12(2):115-8 [10387489.001]
  • [Cites] Anticancer Drugs. 2007 Sep;18(8):973-6 [17667605.001]
  • [Cites] Br Med J (Clin Res Ed). 1981 Jun 20;282(6281):2003-4 [6788166.001]
  • [Cites] N Engl J Med. 1980 Feb 7;302(6):334-5 [7188625.001]
  • [Cites] Transfusion. 1996 Nov-Dec;36(11-12):1016-8 [8937414.001]
  • (PMID = 29147201.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Autoimmune hemolysis / Carboplatin
  •  go-up   go-down


13. McKeage MJ: New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin Investig Drugs; 2005 Aug;14(8):1033-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New-generation platinum drugs in the treatment of cisplatin-resistant cancers.
  • Platinum drugs with altered stable ligands, such as oxaliplatin and satraplatin, produce a different DNA-adduct profile to cisplatin.
  • This results in a distinct therapeutic profile, and clinical trials with these agents demonstrate significant anticancer activity in diseases with inherent or acquired resistance to cisplatin, such as colorectal and prostate cancers as well as previously treated ovarian and germ-cell cancer.
  • An alternative approach to increasing the efficacy associated with platinum therapy is to enhance tumour delivery by coupling platinum drugs with a polymer or encapsulating the agent in a liposome.
  • The early clinical trials of these novel delivery formulations are promising but, as yet, have not confirmed that the delivery of platinum to the tumour cell DNA is increased.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Drug Resistance, Neoplasm / drug effects. Drugs, Investigational / therapeutic use. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16050795.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 78
  •  go-up   go-down


14. Lertkhachonsuk R, Manchana T, Termrungruanglert W, Vasuratna A, Sittisomwong T, Worasethsin P, Sirisabya N, Khemapech N, Tresukosol D: Outcome of recurrent and persistent disease of malignant ovarian germ cell tumor: a retrospective analysis at King Chulalongkorn Memorial Hospital. J Med Assoc Thai; 2006 Feb;89(2):138-44
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of recurrent and persistent disease of malignant ovarian germ cell tumor: a retrospective analysis at King Chulalongkorn Memorial Hospital.
  • Malignant ovarian germ cell tumor has one of the most successful treatment outcomes in gynecological malignancy.
  • More than 80% of the patients can be cured from this rare type of tumor However, patients with recurrent and persistent disease after primary treatment are still the problem of management.
  • The present study has reviewed the treatment outcome of this cancer in King Chulalongkorn Memorial Hospital during the 12 years periodfrom 1993 to 2004.
  • The overall cases of malignant ovarian germ cell tumor were 71 cases, 8 cases had recurrent disease after primary treatment and all cases received platinum-based chemotherapy for the salvage treatment.
  • All patients in this group received long-term survival with median survival time of 87 months.
  • In patients with persistent disease, 10 cases that resisted to first line adjuvant chemotherapy.
  • Cisplatin and Etoposide regimen was applied as second line treatment, but none of these patients received long term response.
  • The overall survival from the treatment of malignant ovarian germ cell tumor in King Chulalongkorn Memorial Hospital was 85.1%.
  • In conclusion, the outcome of treatment in patients with recurrent disease after non-platinum chemotherapy is excellent.
  • Salvage therapy in this group should contain platinum-based regimen.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Neoplasms, Germ Cell and Embryonal / mortality. Neoplasms, Germ Cell and Embryonal / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Biopsy, Needle. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Female. Hospitals, University. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Probability. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Thailand

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • Genetic Alliance. consumer health - Ovarian germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16578998.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


15. Jin Y, Pan LY, Huang HF, Shen K, Wu M, Yang JX, Lang JH: [Comprehensive staging surgery in treatment of malignant ovarian germ cell tumor]. Zhonghua Fu Chan Ke Za Zhi; 2005 Dec;40(12):826-30
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comprehensive staging surgery in treatment of malignant ovarian germ cell tumor].
  • OBJECTIVE: To evaluate the impact of comprehensive staging surgery on relapse and survival of malignant ovarian germ cell tumor (MOGCT).
  • All the data about comprehensive staging surgery during primary surgery were collected, and other factors related to prognosis were also collected at the same time.
  • Seventy-one cases (55.9%) received satisfied cytoreduction with residual tumor < 2 cm, 11 cases (8.7%) with residual tumor > or = 2 cm, and another 45 cases (35.4%) were undetermined.
  • Seventy-five cases (59.1%) received cisplatin, etoposide, and bleomycin (BEP) or cisplatin, vinblastine, and bleomycin (PVB) chemotherapy, 18 cases (14.2%) received vincristine, actinomycin D, cyclophosphamide (VAC) chemotherapy, and 34 cases (26.8%) received other regimens or no chemotherapy.
  • Chemotherapy regimen and residual tumor were the significant factors related to the relapse (P < 0.05).
  • Chemotherapy regimen and residual tumor were also the significant factors related to survival (P < 0.05).
  • CONCLUSIONS: The critical treatment for MOGCT is satisfactory cytoreduction surgery plus standard chemotherapy.
  • [MeSH-major] Germinoma / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Drug Administration Schedule. Dysgerminoma / drug therapy. Dysgerminoma / pathology. Dysgerminoma / surgery. Female. Follow-Up Studies. Humans. Neoplasm Staging. Postoperative Period. Prognosis

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • Genetic Alliance. consumer health - Ovarian germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412329.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Lertkhachonsuk R, Termrungruanglert W, Vasuratna A, Sittisomwong T, Worasethsin P, Tresukosol D: Malignant ovarian germ cell tumor in King Chulalongkorn Memorial Hospital. J Med Assoc Thai; 2005 Sep;88 Suppl 4:S124-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ovarian germ cell tumor in King Chulalongkorn Memorial Hospital.
  • OBJECTIVES: To determine the frequency, characteristics, treatment and outcome of patients with malignant ovarian germ cell tumor (MOGCT) in King Chulalongkorn Memorial Hospital during the period January 1992 - December 2000.
  • STUDY DESIGN: Retrospective descriptive study MATERIAL AND METHOD: All patients with malignant ovarian germ cell tumor in King Chulalongkorn Memorial Hospital during the period January 1992 - December 2000 were analyzed by the characteristics of patients, treatment and outcome.
  • RESULTS: Sixty-six patients with MOGCT were demonstrated in that period with a mean age of 22.6 years old.
  • Eight patients received no adjuvant treatment after surgery due to stage 1A dysgerminoma and immature teratoma stage I grade I.
  • Fifty-six patients received chemotherapy for adjuvant treatment.
  • Salvage therapy in the patients with persistent and recurrent disease was treated in 9 patients, who received a platinum-base of regimen.
  • Two-year survival was 88% with the median time to follow up 24 months.
  • CONCLUSION: MOGCT in King Chulalongkorn Memorial Hospital had clinical characteristics similar to other studies in malignant ovarian germ cell tumor Treatment by VAC regimen still has benefit in selected group.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Ovarian Neoplasms / surgery. Treatment Outcome
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Female. Hospitalization / statistics & numerical data. Hospitals, Urban / utilization. Humans. Incidence. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Salvage Therapy. Survival Analysis. Thailand / epidemiology

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • Genetic Alliance. consumer health - Ovarian germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623016.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


17. Ayas S, Aköz I, Eskicirak E, Karateke A, Bozoklu O: A case of endodermal sinus tumor associated with the first pregnancy and successful management of the second pregnancy: a case report and review of the literature. Eur J Gynaecol Oncol; 2007;28(2):155-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of endodermal sinus tumor associated with the first pregnancy and successful management of the second pregnancy: a case report and review of the literature.
  • BACKGROUND: Pregnancy complicated by endodermal sinus tumor (EST) of the ovary has rarely been reported.
  • CASE: A huge ovarian EST causing bowel obstruction was found in a 22-year-old patient at 34 weeks of gestation.
  • Abnormally high alpha-fetoprotein (AFP) levels suggested a malignant germ cell tumor of the ovary.
  • The patient was submitted to cesarean section and fertility sparing surgery, and then received four courses of combination chemotherapy.
  • There was no evidence of recurrence 19 months after initial treatment but transvaginal ultrasound (US) evaluation showed an intrauterine pregnancy of six weeks.
  • CONCLUSIONS: Successful outcome of a second pregnancy is possible after treatment with fertility sparing surgery and combination chemotherapy for an endodermal sinus tumor associated with a first pregnancy.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / drug therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Pregnancy. Pregnancy Outcome. Pregnancy Trimester, Third. Treatment Outcome. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17479685.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 34
  •  go-up   go-down


18. Shen K, Lang J, Huang H: [Treatment of childhood genital malignancies]. Zhonghua Fu Chan Ke Za Zhi; 2001 Jun;36(6):360-3
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of childhood genital malignancies].
  • OBJECTIVE: To present the clinical profile and the result of treatment in childhood genital malignancies.
  • METHODS: Twenty seven childhood patients (< 12 years) with genital malignancies diagnosed and treated in Peking Union Medical College hospital were analyzed retrospectively focusing on the clinical characteristics and outcome of the treatment.
  • RESULTS: Patients ranged in age from 2 to 12 years with mean 6.5 years at diagnosis.
  • Of the 27 patients, 23 had ovarian malignancies including 21 (77.8%) germ cell tumor.
  • Four of the patients had extragonadal tumors with 2 endodermal sinus tumor of the vagina, and 2 embryonic rhabdomysarcoma.
  • In ovarian malignancies, abdominal mass and abdominal pain were main clinical features accounting for 77.8% and 74.1% respectively.
  • In vaginal malignancies, vaginal bleeding and polypoid tumor of the vagina were important clinical manifestations.
  • 91.3% (21/23) of the patients underwent only unilateral salpingo-oophorectomy with preservation of contralateral ovary and the uterus.
  • Childhood genital malignancies were very sensitive to the chemotherapy.
  • Postoperative vincristine, actinomycine, cyclophosphamide (VAC) or cisplatine, vincristine, blyomycine (PVB) chemotherapy was individualized according to the tumor site, International Federation of Gynecology and obstetrics stage and histopathology.
  • Survival rate in our series was 71.4% during the follow-up time (mean 47.4 months).
  • CONCLUSIONS: Malignant germ cell tumor of the ovary is the most common tumor in the childhood genital malignancies.
  • Principle of primary surgery is preservation of fertility and chemotherapy is also considered as a very important treatment modality.
  • [MeSH-major] Genital Neoplasms, Female / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Drug Administration Schedule. Female. Humans. Retrospective Studies. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11783136.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; PVB protocol; VAC protocol
  •  go-up   go-down


19. Jin Y, Pan LY, Huang HF, Shen K, Wu M, Yang JX, Lang JH: [Lymphadenectomy in the treatment of malignant ovarian germ cell tumor]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Dec;27(6):743-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphadenectomy in the treatment of malignant ovarian germ cell tumor].
  • OBJECTIVE: To evaluate the impact of lymphadenectomy on the relapse and survival of malignant ovarian germ cell tumor (OGCT).
  • All the data about lymphadenectomy during primary and secondary surgery were collected, and other factors related to prognosis were also collected at the same time.
  • In the primary treatment, International Federation of Gynecology and Obstetrics (FIGO) staging, chemotherapy regimen, residual tumor and lymphadenectomy were the significant factors related to the relapse.
  • After being stratified for the chemotherapy regimen, lymphadenectomy was not significantly related to the relapse in bleomycin +etoposide +cisplatin or cisplatin +vincristine +bleomycin regimen group, and lymphadenectomy could prevent relapse in no chemotherapy or other chemotherapy regimen group.
  • In relapsed patients, only residual tumor was significantly related to survival time after relapse.
  • Although lymphadenectomy provides important information for prognosis, they provide little benefit to those patients already requiring chemotherapy based on the original operative findings.
  • [MeSH-major] Germinoma / surgery. Lymph Node Excision / methods. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Retroperitoneal Space. Retrospective Studies

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • Genetic Alliance. consumer health - Ovarian germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447650.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Haibin Z, Yue J, Yaxian X: Primary yolk sac tumor of the omentum: a case report and literature review. Eur J Gynaecol Oncol; 2010;31(6):682-4
Genetic Alliance. consumer health - Yolk sac tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary yolk sac tumor of the omentum: a case report and literature review.
  • BACKGROUND: Yolk sac tumor (YST) is the second most common malignant ovarian germ cell tumor, while a YST arising in the omentum is an exceedingly rare malignancy.
  • CASE: A 44-year-old woman was admitted with a history of abdominal distension of a month's duration.
  • Explorative findings revealed a large omental mass with a small implantation on the surface of the left ovary.
  • The patient was treated with total abdominal hysterectomy with bilateral salpingo-oophorectomy and infracolic omentectomy followed by four cycles of bleomycin, etoposide, and cisplatin combination chemotherapy.
  • She has remained free of the disease for seven months after completion of therapy.
  • The case of omental YST must be seriously considered once the tumor shows omentum thickening with elevated AFP serum levels.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / therapy. Omentum / surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Hysterectomy. Ovariectomy. Peritoneum / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319517.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


21. Lo Curto M, D'Angelo P, Cecchetto G, Klersy C, Dall'Igna P, Federico A, Siracusa F, Alaggio R, Bernini G, Conte M, De Laurentis T, Di Cataldo A, Inserra A, Santoro N, Tamaro P, Indolfi P: Mature and immature teratomas: results of the first paediatric Italian study. Pediatr Surg Int; 2007 Apr;23(4):315-22
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Teratoma is the most common germ cell tumour in childhood; mature (MT) and immature teratomas (IT) are benign tumours, but if they recur, they can be in some cases malignant.
  • Clinical data, treatment and results were all analysed.
  • Initial evaluation and subsequent follow up included clinical examination, tumour markers and imaging procedures.
  • Chemotherapy (CT) with Vinblastine, D: -actinomycin and cyclophosphamide was indicated for extra-testicular IT grade 2 or 3.
  • MT was diagnosed in 127 patients (93 F and 34 M, age 1-192 months, median 24): 58 patients had gonadic tumour (23 testicular, 35 ovaric), 69 extragonadic (45 sacrococcygeal, 11 mediastinic, 7 retroperitoneal, 6 in other sites).
  • The T grading was 1 in 14 cases, 2 in 26, 3 in 16; 28 had gonadic T (17 ovary, 11 testis), 28 extragonadic (sacrococcygeal 19, mediastinic 3, retroperitoneal 2, other sites 4).
  • CT was administered in eight patients; 15/182 patients relapsed (1 in a metastatic site) and in 5/15 the relapse showed malignant histology.
  • Seven MT (5.5%) relapsed (five sacrococcygeal, one retroperitoneal, one mediastinic): surgery at diagnosis had been complete in five and with residual in two; the relapse was malignant in two patients with sacrococcygeal (sc) tumours, who had a complete resection and a partial resection respectively.
  • Eight IT (14.2%) relapsed (four ovary, three sc, one retroperitoneal).
  • A malignant recurrence occurred in two patients with sc tumours (after partial resection in one and after biopsy + CT in one) and in one patient with ovarian IT after a partial resection.
  • All the patients underwent surgical excision of the recurred mass; CT according to Protocol for Malignant GCT was administered to those who had malignant recurrence; 122/126 patients with MT and 53/56 with IT are alive without disease with a follow up of 8-144 months (median 56).
  • Two patients with malignant relapse (one with sc MT, one with sc IT) died because of the progression of the disease.
  • At Cox analysis no significant difference in EFS was found regarding age and site of the primary tumour, while females (P = 0.011), patients with grade 1-3 histology (P = 0.025) and patients with incomplete resection appeared at higher risk of death or relapse (P < 0.001), with a seven, three and eightfold increase in risk, respectively.
  • The number of patients treated with CT is not sufficient to evaluate the efficacy of CT in avoiding malignant relapse.
  • [MeSH-major] Ovarian Neoplasms / epidemiology. Teratoma / epidemiology. Testicular Neoplasms / epidemiology
  • [MeSH-minor] Age Distribution. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Incidence. Infant. Infant, Newborn. Italy / epidemiology. Male. Neoplasm Staging. Prospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):228-34 [9293455.001]
  • [Cites] J Pediatr Surg. 2001 Jan;36(1):12-7 [11150431.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2137-43 [10561269.001]
  • [Cites] Med Pediatr Oncol. 2003 Nov;41(5):417-25 [14515380.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1075-8; discussion 1078-9 [1403540.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):620-4 [9053485.001]
  • [Cites] J Pediatr Surg. 1987 Mar;22(3):274-7 [3559872.001]
  • [Cites] Med Pediatr Oncol. 1998 Jul;31(1):8-15 [9607423.001]
  • [Cites] Ann Surg. 1965 Dec;162(6):1091-5, 1100 [5845591.001]
  • [Cites] Crit Rev Oncol Hematol. 1990;10(2):99-110 [2163259.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):171-6 [9498381.001]
  • [Cites] Cancer. 1989 May 1;63(9):1657-67 [2467734.001]
  • [Cites] Pediatr Blood Cancer. 2004 Feb;42(2):169-75 [14752882.001]
  • [Cites] Crit Rev Oncol Hematol. 1990;10(2):89-98 [1694438.001]
  • [Cites] Med Pediatr Oncol. 1993;21(6):395-401 [8390599.001]
  • [Cites] Am J Obstet Gynecol. 1999 Aug;181(2):353-8 [10454682.001]
  • [Cites] J Pediatr Surg. 1974 Jun;9(3):389-98 [4843993.001]
  • [Cites] Cancer. 1976 May;37(5):2359-72 [1260722.001]
  • [Cites] AJR Am J Roentgenol. 1981 Aug;137(2):395-8 [6789651.001]
  • (PMID = 17333214.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


22. Kitajima Y, Endo T, Hayashi T, Ishioka S, Baba T, Honnma H, Saito T: A successful IVF-pregnancy in a patient who underwent conservative surgery followed by a regimen of cisplatin, vinblastine and peplomycin to treat an advanced ovarian mixed germ cell tumour: a case report. Hum Reprod; 2007 Mar;22(3):850-2
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A successful IVF-pregnancy in a patient who underwent conservative surgery followed by a regimen of cisplatin, vinblastine and peplomycin to treat an advanced ovarian mixed germ cell tumour: a case report.
  • Mixed germ cell tumours of the ovary, one type of malignant ovarian germ cell tumours (MOGCTs), are rare gynaecologic cancers usually affecting young women.
  • We report the case of a patient with an advanced ovarian mixed germ cell tumour who underwent fertility-saving surgery followed by a chemotherapy regimen of cisplatin, vinblastine and peplomycin.
  • To the best of our knowledge, the patient is the first to be treated successfully with the combination chemotherapy regimen and then conceive safely using assisted reproductive technology (ART).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fertilization in Vitro. Neoplasms, Germ Cell and Embryonal / therapy. Ovarian Neoplasms / therapy. Pregnancy, Multiple
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Infant, Newborn. Infertility, Female / etiology. Male. Peplomycin / administration & dosage. Peplomycin / therapeutic use. Peritoneal Diseases / complications. Peritoneal Diseases / pathology. Pregnancy. Pregnancy Outcome. Tissue Adhesions. Twins. Vinblastine / administration & dosage. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067995.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 56H9L80NIZ / Peplomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; PVP protocol 4
  •  go-up   go-down


23. Patterson DM, Rustin GJ: Controversies in the management of germ cell tumours of the ovary. Curr Opin Oncol; 2006 Sep;18(5):500-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in the management of germ cell tumours of the ovary.
  • PURPOSE OF REVIEW: Ovarian germ cell tumours are rare, but curable at all stages of disease.
  • Also during pregnancy, AFP-L2 looks to be a promising tumour marker in detecting relapse.
  • Malignant transformation of mature teratomas may be predicted by preoperative squamous cell antigen and tumour size.
  • OCT4 immunohistochemistry has been shown to be a very useful adjunct in the diagnosis of dysgerminomas.
  • Patients receiving cisplatin-based chemotherapy are at a higher risk of developing cardiovascular risk factors.
  • There is a hint that high-dose chemotherapy may play a role in relapsed patients.
  • SUMMARY: Rarity of the disease means many controversies are difficult to resolve, with much reliance on using data from testicular cancer studies.
  • Many clinicians still advocate adjuvant chemotherapy for stage I nondysgerminomatous tumours of grade 2 and above despite good evidence that surveillance is a safe option, and increasing concerns about life-threatening long-term effects of treatment.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Female. Humans. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894300.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 58
  •  go-up   go-down


24. Li H, Hong W, Zhang R, Wu L, Liu L, Zhang W: Retrospective analysis of 67 consecutive cases of pure ovarian immature teratoma. Chin Med J (Engl); 2002 Oct;115(10):1496-500
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of 67 consecutive cases of pure ovarian immature teratoma.
  • OBJECTIVE: To investigate the development regularity, treatment methods and prognosis of ovary immature teratoma (POIT).
  • From the 1980s, this was followed by four-cycles of combination chemotherapy (VAC, PVB or BEP x 3 cycles) as post-operative adjuvant therapy.
  • Combined chemotherapy and multiple operations were performed for advanced and recurrent lesions.
  • The chief prognostic factors for this disease are clinical stage, pathological grade and adequate treatment.
  • It is characterized by the fact that recurrent tumors may be converted back to mature ones as time goes on.
  • With chemotherapy, these is a good opportunity to rescue those patients with recurrent tumors.
  • At present, treatment of POIT gives the most satisfactory results among all malignant ovarian germ cell tumor types.
  • Tests of serum specific tumor markers (CA19-9, AFP, CA125, CEA) performed preoperatively or before chemotherapy and during follow-up have been found helpful in the evaluation of prognosis.
  • [MeSH-major] Ovarian Neoplasms / mortality. Teratoma / mortality
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Child, Preschool. Female. Humans. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12490095.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Tangjitgamol S, Hanprasertpong J, Manusirivithaya S, Wootipoom V, Thavaramara T, Buhachat R: Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes. Acta Obstet Gynecol Scand; 2010;89(2):182-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes.
  • OBJECTIVE: To evaluate clinico-pathological features, treatment, survival, and prognostic factors of patients with malignant ovarian germ cell tumors.
  • POPULATION: Malignant ovarian germ cell tumor patients treated between January 1996 and December 2007.
  • Patients with malignant tumors arising from benign cystic teratoma were excluded.
  • Of 124 patients with available follow-up data, 22 did not receive adjuvant treatment; 1 had whole abdominal radiation; and 101 had chemotherapy.
  • Only preoperative tumor marker elevation was a significant poor prognostic factor for PFS.
  • CONCLUSIONS: Malignant ovarian germ cell tumors have a good prognosis with conservative surgical treatment.
  • Chemotherapy is important.
  • Elevated preoperative serum tumor markers are a poor prognostic factor for PFS.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / mortality. Neoplasms, Germ Cell and Embryonal / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Disease-Free Survival. Female. Humans. L-Lactate Dehydrogenase / blood. Neoplasm Recurrence, Local / pathology. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Young Adult. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961281.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


26. Zuntová A, Sumerauer D, Teslík L, Kabícková E, Koutecký J: [Mixed germ cell tumours of the ovary in childhood and adolescence]. Cesk Patol; 2004 Jul;40(3):92-101
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed germ cell tumours of the ovary in childhood and adolescence].
  • Mixed germ cell tumours of the ovary are rare malignant neoplasms containing combinations of two or more types of germ cell elements.
  • The aim of the study was to review biopsy examinations, medical records, treatment strategy, follow-up and outcome of all girls treated for mixed germ cell tumour of the ovary at the Department of Pediatric Oncology, University Hospital Motol during the period 1979-2002.
  • The clinical data on surgical treatment, chemotherapy and radiotherapy used and follow-up information were obtained in all girls.
  • Sixteen girls with mixed germ cell tumour of the ovary, age range 3 years 11 months to 17 years 8 months (median 12 years) were treated.
  • All girls presented with unilateral tumour of the ovary and all underwent surgery as an initial treatment.
  • The original diagnosis of mixed histology was confirmed in all cases; in five cases the tumour contained three histologic components, in eleven cases the tumour consisted of two germ cell types.
  • All tumours contained elements of yolk sac tumour, followed by immature teratoma, embryonal carcinoma, dysgerminoma and mature teratoma.
  • At the time of diagnosis three patients had stage I disease, four patients stage II, seven stage III and two stage IV disease.
  • All patients were treated with chemotherapy after surgery, predominantly with platinum-based regimens (PVB, BEP).
  • Overall survival and event-free survival were 80% and 81.3% respectively (median follow-up time 7.6 years).
  • Three patients have died from the disease, two progressed on treatment (MAC), one girl relapsed three months after finishing therapy, no further therapy was administered.
  • One girl underwent resection of tumour of her remaining ovary 24 months after original diagnosis.
  • Microscopic examination should be extensive and careful to find out all types of malignant germ cell elements.
  • Platinum based chemotherapy is effective in the management of children and adolescents with mixed germ cell tumors of the ovary.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493415.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


27. Rzepka-Górska I, Błogowska A, Zajaczek S, Zielińska D: [Germinal cell tumors in young and adolescent girls]. Ginekol Pol; 2003 Sep;74(9):840-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Germinal cell tumors in young and adolescent girls].
  • OBJECTIVE: Germ cell tumours are the most common ovarian tumours in childhood and adolescence.
  • This diverse group of tumours derives from germ cells.
  • DESIGN: The aim of this work is presentation of germ cell tumours in the material from our clinic with characteristic clinical features, the scope of operation and effects of many years of observation.
  • MATERIALS AND METHODS: We treated 109 girls with germ cell tumours of the ovary: 13 had malignant tumours: there were 7 patients with dysgerminomas, 2 with endodermal sinus tumour of the ovary, 3 with immature teratomas, 1 with carcinoma embryonale.
  • There can be problems with diagnosis of the syndrome, because developmental features imitate the onset of normal puberty.
  • It must be suggested that patients of stage I who wish to preserve childbearing function may be treated with unilateral salpingoophorectomy and adjuvant chemotherapy.
  • Monitoring of the treatment is connected with measurement of biochemical markers.
  • Some of these markers are useful for monitoring of response to therapy.
  • Cytological smears and biopsy specimens from the remaining ovary, peritoneum and subdiaphragmatic area should be obtained laparoscopically.
  • CONCLUSIONS: The sift ultrasonographic investigations can be helpful in the early diagnosis of germ cell tumours of the ovary in girls.
  • Fertility sparing operative treatment is preferred when karyotype is normal.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / blood. Child. Combined Modality Therapy. Dysgerminoma / pathology. Dysgerminoma / therapy. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Female. Germinoma / pathology. Germinoma / therapy. Gonadoblastoma / pathology. Gonadoblastoma / therapy. Gonadotropins / blood. Gonadotropins / genetics. Humans. Poland. Risk Factors. Teratoma / pathology. Teratoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14674134.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gonadotropins
  •  go-up   go-down


28. Palenzuela G, Martin E, Meunier A, Beuzeboc P, Laurence V, Orbach D, Frappaz D: Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary. Ann Surg; 2008 Nov;248(5):836-41
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary.
  • BACKGROUND: The management of malignant germ cell tumors of the ovary (OMGCT) requires multidisciplinary expertise.
  • PATIENTS AND METHODS: Data concerning diagnosis, surgery, and medical decisions were reviewed for all patients seen for postoperative management of OMGCT at the Centre Léon Bérard in Lyon and the Institut Curie in Paris between 1985 and 2003.
  • Sixty patients aged 0.4 to 27.9 years (mean 12.8 years) at diagnosis were included.
  • Relapses occurred in 8 of 24 stage I tumors that were observed (0/8 stage Ia; 5/13 stage Ix (P = 0.044) and 3/3 stage Ic) versus 0/14 stage I treated by adjuvant chemotherapy (P = 0.0015).
  • The risk of relapse was significantly increased if patients underwent postsurgical observation ((HR) = 4.5 (95% CI, 1.5 to 13.3)), and when the tumor contained yolk sac tumor (HR = 7.3 (95% CI, 2.3 to 22.7)).
  • There was no significant prognostic value for age, stage, level of tumor markers at diagnosis, type of surgery, and type of chemotherapy.
  • Patients with stages Ix and Ic tumors may benefit from adjuvant chemotherapy.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Dysgerminoma / diagnosis. Dysgerminoma / surgery. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Fallopian Tubes / surgery. Female. Humans. Neoplasm Staging. Ovariectomy. Radiotherapy, Adjuvant. Retrospective Studies. Teratoma / diagnosis. Teratoma / pathology. Teratoma / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948812.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down






Advertisement